Core Viewpoint - BioAtla, Inc. is implementing a 50-for-1 share consolidation to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement of $1.00, effective April 6, 2026 [1][2]. Company Actions - The share consolidation will convert every fifty shares of common stock into one share, with no fractional shares issued; stockholders entitled to fractional shares will receive cash equivalent [4]. - The consolidation was approved by stockholders at a special meeting on March 23, 2026, as part of a merger agreement with its wholly-owned subsidiary, BA Merger Sub, Inc. [3]. Impact on Stock and Options - Following the consolidation, the number of shares available under the company's equity incentive plan and employee stock purchase plan will be proportionately reduced, and adjustments will be made to the exercise prices and number of shares for outstanding stock options and warrants [5]. Stockholder Information - Stockholders holding shares electronically will not need to take action to receive post-consolidation shares, while those with shares through brokers will have their positions automatically adjusted [6]. Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, with a robust pipeline including ADCs and T cell engagers [7]. - The company has over 780 active patent matters, with more than 500 issued patents, covering its CAB platform technology and products [7]. Clinical Pipeline - BioAtla's clinical pipeline includes Ozuriftamab vedotin (CAB-ROR2-ADC) in Phase 3 for OPSCC and Mecbotamab vedotin (CAB-AXL-ADC) in Phase 2 for multiple solid tumor indications [8][13]. - The company is also developing BA3182, a bispecific T cell engager antibody, currently in Phase 1 for advanced adenocarcinoma [10]. Market Opportunity - Ozuriftamab vedotin targets a market opportunity exceeding $7 billion worldwide, particularly for HPV+ cancers, and has received Fast Track Designation from the FDA for treating recurrent or metastatic squamous cell carcinoma of the head and neck [11].

Core Insights - BioAtla, Inc. reported its financial results for the full year and fourth quarter ended December 31, 2025, highlighting a focus on advancing its clinical programs while exploring strategic options to maximize shareholder value [1][3]. Corporate Updates - The company initiated a formal process to explore strategic options, including the potential sale of assets and partnerships, engaging Tungsten Advisors as its exclusive financial advisor [3]. - A reduction in force and cost-containment measures were implemented to align resources with near-term priorities, affecting the timing and scope of clinical development programs [4]. - The ongoing Phase 1 study of BA3182 in adenocarcinomas remains a priority, with the company committed to its clinical development despite potential delays [4]. Financial Results - Research and development (R&D) expenses for Q4 2025 were $8.0 million, down from $11.7 million in Q4 2024. For the full year, R&D expenses totaled $43.6 million, compared to $63.1 million in 2024, primarily due to lower program development costs and reduced headcount-related expenses [5]. - Collaboration and other revenue for Q4 2025 was $2.0 million, reflecting a milestone payment from Context Therapeutics, compared to $11.0 million for the full year 2024 [6]. - General and administrative (G&A) expenses decreased to $3.3 million in Q4 2025 from $4.6 million in Q4 2024, with full-year G&A expenses at $17.7 million compared to $21.8 million in 2024 [7]. - The net loss for Q4 2025 was $9.8 million, an improvement from a net loss of $14.9 million in Q4 2024. The full-year net loss was $59.6 million, down from $69.8 million in 2024 [8]. Cash Position - As of December 31, 2025, cash and cash equivalents were $7.1 million, a significant decrease from $49.0 million at the end of 2024 [10][23]. - The company expects to extend its runway through cost reductions and the utilization of a Standby Equity Purchase Agreement while pursuing strategic options [10]. Clinical Pipeline - BioAtla is advancing several clinical assets, including BA3182, a bispecific T-cell engager antibody for advanced adenocarcinoma, and Ozuriftamab Vedotin (Oz-V), targeting oropharyngeal squamous cell carcinoma [13][15]. - Oz-V has received Fast Track Designation from the FDA for treating recurrent or metastatic squamous cell carcinoma of the head and neck, with a potential market opportunity exceeding $7 billion [15]. Patent Portfolio - BioAtla holds extensive patent coverage for its CAB platform technology, with over 780 active patent matters, including more than 500 issued patents, covering various methods and compositions related to its product candidates [11].

Core Viewpoint - BioAtla, Inc. is exploring strategic options to maximize shareholder value, including potential asset sales and partnerships, while implementing a significant restructuring plan to reduce operating expenses by approximately 70% [1][2]. Company Overview - BioAtla is a clinical-stage biotechnology company based in San Diego, focusing on Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [3]. - The company utilizes a proprietary CAB platform technology to develop novel monoclonal and bispecific antibodies, aiming for selective targeting and reduced toxicity compared to traditional antibodies [3]. - BioAtla holds over 780 active patent matters, with more than 500 issued patents, covering methods of making and manufacturing CAB product candidates [3]. Clinical Pipeline - BioAtla's clinical pipeline includes several assets at various stages: - Ozuriftamab vedotin (CAB-ROR2-ADC) is in Phase 3 for treating oropharyngeal squamous cell carcinoma (OPSCC) and has potential applications in HPV+ cancers, representing a market opportunity of over $7 billion [8]. - Mecbotamab vedotin (CAB-AXL-ADC) is in Phase 2 for multiple solid tumor indications, including mKRAS NSCLC and soft tissue sarcoma [10]. - Evalstotug (CAB-CTLA-4) is in Phase 2, designed for safer combination therapies with anti-PD-1 agents [11]. - BA3182 (CAB-EpCAM x CAB-CD3) is in Phase 1 for advanced adenocarcinoma [7]. Strategic Actions - The company has engaged Tungsten Advisors as its exclusive strategic financial advisor to assist in evaluating potential transactions [2]. - The restructuring plan aims to retain essential employees while significantly reducing the workforce to enhance cost containment [1].

Core Insights - BioAtla, Inc. and GATC Health Corp. announced a special purpose vehicle (SPV) transaction to advance ozuriftamab vedotin (Oz-V) in a Phase 3 study for 2L+ oropharyngeal squamous cell carcinoma (OPSCC) [1][4] Financial Aspects - BioAtla will receive an initial funding of $5 million for operational and clinical trial expenses, with an additional $35 million expected to close in Q1 2026 [2][3] - Inversagen AI, LLC will hold a 35% ownership stake in Oz-V, while BioAtla retains 65% ownership across all indications after the transaction [3][8] Clinical Development - The Phase 3 trial for Oz-V is anticipated to begin enrollment in early 2026, with a clear path for potential accelerated approval in the US [4][6] - Oz-V targets ROR2, a receptor linked to tumor progression and cellular senescence, with potential applications extending to HPV-positive cancers, representing a market opportunity exceeding $7 billion globally [7][9] Strategic Collaboration - BioAtla and GATC Health plan to collaborate with Inversagen AI for the research and development of CAB senolytic therapies, maintaining rights to cancer therapeutic applications [3][5] - The partnership aims to leverage BioAtla's CAB platform technology to enhance the precision of senolytic therapies, addressing chronic inflammation and tumor progression [5][11] Technology Overview - The CAB technology developed by BioAtla is designed to selectively target diseased tissues in inflammatory conditions, enhancing therapeutic efficacy while minimizing toxicity [11][12] - ROR2-targeting agents may represent a new class of senolytics, potentially improving tissue function and reducing chronic inflammation [10]

Core Insights - BioAtla, Inc. presented clinical data showing that Mecbotamab Vedotin (Mec-V) achieved a median overall survival (OS) of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, compared to approximately 12 months with approved agents [1][4][7] - The safety profile of Mec-V, both as a monotherapy and in combination with anti-PD-1 antibody, was manageable and consistent with its mechanism of selectively targeting the tumor microenvironment [1][2][4] Clinical Trial Details - In a Phase 2 clinical trial, 79 patients with advanced soft tissue sarcomas were treated with Mec-V, either as monotherapy (n=54) or in combination with anti-PD-1 antibody (n=25) [3] - A focused efficacy analysis was conducted on a subset of 44 patients who had treatment-refractory leiomyosarcoma, liposarcoma, or undifferentiated pleomorphic sarcoma [3] Efficacy and Safety Data - The median OS was 21.5 months across all patients, with 22.9 months in the combination arm and 18.4 months in the monotherapy arm [7] - The 12-month OS rate was 73%, significantly higher than the approximately 50% historically reported for approved agents in similar populations [7] - The disease control rate (DCR) was 52% across all patients, with two patients achieving partial responses [7] - Adverse events were generally low-grade and manageable, with no treatment-related deaths reported [7] Presentation Information - The data was presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlighting the potential of Mec-V to extend survival in patients with limited treatment options [1][6]

Core Insights - BioAtla, Inc. presented clinical data showing that Mecbotamab Vedotin (Mec-V) achieved a median overall survival (OS) of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, significantly higher than the approximately 12 months observed with approved agents [1][4][7] - The safety profile of Mec-V, both as a monotherapy and in combination with anti-PD-1 antibody, was manageable and consistent with its mechanism of selectively targeting the tumor microenvironment [1][2][4] Clinical Trial Details - In a Phase 2 clinical trial, 79 patients with advanced soft tissue sarcomas were treated with Mec-V, either as monotherapy (n=54) or in combination with anti-PD-1 antibody (n=25) [3] - A focused efficacy analysis was conducted on a subset of 44 patients who had treatment-refractory leiomyosarcoma, liposarcoma, or undifferentiated pleomorphic sarcoma [3] Efficacy and Safety Data - The median OS was 21.5 months across all patients, with 22.9 months in the combination therapy arm and 18.4 months in the monotherapy arm [7] - The 12-month OS rate was 73%, compared to approximately 50% historically reported for similar populations treated with approved agents [7] - The disease control rate (DCR) was 52% across all patients, with two patients achieving partial responses [7] - Adverse events were generally low-grade and manageable, with no treatment-related deaths reported [7] Presentation Information - The data was presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlighting the potential of Mec-V to extend survival in patients with limited treatment options [1][6]

Core Insights - BioAtla, Inc. is presenting clinical data on its investigational antibody-drug conjugate, ozuriftamab vedotin (Oz-V), at the International Papillomavirus Society Conference, focusing on its application in treating advanced HPV+ oropharyngeal squamous cell carcinoma (OPSCC) [1][2] Company Overview - BioAtla is a global clinical-stage biotechnology company based in San Diego, California, and Beijing, China, specializing in the development of Conditionally Active Biologic (CAB) antibody therapeutics [6] - The company utilizes its proprietary CAB platform technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting and greater efficacy with lower toxicity [6] Product Details - Ozuriftamab vedotin (Oz-V) targets ROR2, a receptor tyrosine kinase overexpressed in various solid tumors, including OPSCC, driven by HPV infection [4] - In a Phase 2 trial, Oz-V demonstrated an overall response rate (ORR) of 45% and a disease control rate (DCR) of 100% in refractory patients, with a median overall survival (OS) of 11.6 months [4] - The FDA has granted Fast Track Designation to Oz-V for treating recurrent or metastatic squamous cell carcinoma of the head and neck [4] Market Opportunity - The global market opportunity for second-line and beyond OPSCC is over $1 billion, while for first-line HPV+ tumors, it is potentially over $7 billion [5] - OPSCC is rapidly increasing, with HPV infections accounting for approximately 80% of cases in the United States [5]

Core Insights - BioAtla, Inc. announced preliminary clinical data from a Phase 1 study of BA3182, a bispecific T-cell engager targeting EpCAM and CD3, at the ESMO Congress 2025, highlighting its potential for treating treatment-refractory metastatic adenocarcinoma [1][3] Group 1: Clinical Data and Efficacy - BA3182 shows a manageable safety profile with preliminary evidence of antitumor activity [4] - Prolonged tumor control observed with increasing doses of BA3182, including a confirmed partial response at 0.6 mg in a patient with intrahepatic cholangiocarcinoma without progression for over 6 months [6] - Among patients treated at doses of 0.6 mg and higher, there was a higher rate of stable disease and prolonged treatment intervals compared to those receiving lower doses [13] Group 2: Safety Profile - Adverse events were generally transient and manageable, with only 2 cases of cytokine release syndrome reported [6] - No treatment-related deaths occurred, and only one patient discontinued treatment due to an adverse event [6] - Safety profile supports continued dose escalation, with the maximally tolerated dose not yet defined [6] Group 3: Technology and Mechanism - BA3182 is designed to selectively bind within the acidic tumor microenvironment, reducing on-target, off-tumor toxicity associated with traditional antibodies [2][9] - The CAB technology utilized by BioAtla activates only in diseased microenvironments, aiming for more selective targeting and lower toxicity compared to conventional therapies [10] Group 4: Market Potential - BA3182 has the potential to serve over one million patients globally, indicating a significant market opportunity for BioAtla [3]

Core Viewpoint - BioAtla, Inc. is set to discuss its financial results for Q2 2025 and provide business highlights during a conference call on August 7, 2025 [1][2] Company Overview - BioAtla is a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] - The company operates in San Diego, California, and Beijing, China, through a partnership with BioDuro-Sundia for preclinical development services [3] - BioAtla utilizes its proprietary CAB platform technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - The company holds extensive patent coverage with over 780 active patent matters, including more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3] Product Development - BioAtla's first dual CAB bispecific T-cell engager antibody, BA3182, is in Phase 1 development, targeting EpCAM, which is commonly expressed in adenocarcinomas [3] - The company has two first-in-class CAB programs in Phase 2 clinical testing: mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC) [3] - The Phase 2 CAB-CTLA-4 antibody, evalstotug, is designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors like anti-PD-1 antibody [3]

Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] Presentation Details - BioAtla will present two preclinical posters at the 2025 American Association for Cancer Research (AACR) conference in Chicago from April 25–30, 2025 [1][2] - The first poster discusses novel senolytic targets and CAB-based drug conjugates for eliminating senescence-associated secretory phenotype cells [2] - The second poster highlights BA3361, a tumor-selective CAB anti-Nectin4 antibody-drug conjugate that enhances therapeutic efficacy in pancreatic cancer [2] Company Overview - BioAtla operates in San Diego, California, and Beijing, China, utilizing its proprietary CAB platform technology to develop monoclonal and bispecific antibodies [3] - The CAB technology aims for selective targeting, greater efficacy with lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - The company holds over 780 active patent matters, with more than 500 issued patents covering its CAB technology and products [3][4] Technology Highlights - The CAB anti-Nectin4-ADC shows differentiated preclinical activity with superior efficacy compared to enfortumab vedotin in various cancer models [4] - CAB technology offers a new generation of biologics with an increased safety margin and therapeutic index, targeting senescence-related cells in cancer and age-related diseases [4]